Respiratory Infections

The ideal time to act on COVID-19 was in January, says public health expert Raj Bhopal.

The US CDC has been engaged in a back and forth with media for several days after reductionist reporting on immunity related to COVID-19 suggested categorical proof of antibody based immunity to reinfection.

Use of an IL-6 inhibitor has the potential to prevent the cytokine storm caused by severe COVID-19 infection.

July ended with nearly 100,000 new cases among children in the US. What does that mean for public and school reopenings?

SalivaDirect is unique in that it does not require a particular type of swab or collection device; any sterile container is suitable for saliva collection with the test.

Armand Balboni, MD, PhD, discusses progress toward FDA authorization and/or approval of favipiravir for COVID-19 as a prophylactic measure.

Walter A. Orenstein, MD, answers audience questions collected during our Vaccine Race webinar.

A look at the processes and clinical practices at place to assure candidate safety during the COVID-19 vaccine race.

How can we bridge the divide between the public and public health? Raj Bhopal argues for a strong but supportive pandemic response.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

The modified adenovirus-strain candidate did not reach phase 3 assessment, and was criticized by the WHO for being rushed through assessment.

The antiviral is currently emergency authorized for treatment of severe COVID-19.

A breakdown of how COVID-19 infection was not managed well in hospitals and ICUs early on.

The clearance for the phase 2 preventive trial will seek the oral antiviral's benefit in elderly care facilities.

The authorization is for an amplicon-based next-generation sequencing test from Helix.

New joint data from the American Academy of Pediatrics and Children's Hospital Association shows 3 states make up one-fourth of all pediatric cases.

The island country of 5 million declared the pandemic over in approximately 100 days. A team of clinicians explain the decision-making and rationale which drove their successes.

A Harvard professor and study author discusses new findings showing the heightened risk of healthcare worker infection.

Raj Bhopal, BSc MD, MPH, addresses the nuances of competing ethical priorities societies face amid COVID-19, alongside political battles and terms like “herd immunity.”

David Ho, MD, shares insight into the public and scientific health shortcomings which burdened the nation back in March.

Patrick Soon-Shiong and Dr. Adam Brufsky have an open minded discussion on the dangers and potential lessons of the course Swedish health officials recommended the country take over the SARS-CoV-2 pandemic.

Will screening be based on symptoms alone? How accurate and fast must tests be?

The letter was penned by IDSA President Thomas M. File, Jr., MD, MSc, FIDSA and HIVMA Chair Judith Feinberg, MD, FIDSA on behalf of their organizations.